$20 Million in a Series A Funding for 3D Bioprinting of Human Tissue

$20 Million in a Series A Funding for 3D Bioprinting of Human Tissue

Posted on Updated on

According to Sam Davies, “We are developing a new wave of solutions that have the potential to transform how we heal injury and disease.”

According to Tamer Mohamed, CEO, Aspect Biosystems, “We are thrilled to close this important institutional financing round with a group of world-class investors who believe in our bold vision. This funding speaks to the power of our technology and strategy in addressing multiple applications in therapeutic discovery and regenerative medicine, and will allow us to accelerate internal innovation and expand our global partnerships. With our technology platform, interdisciplinary team of scientists and engineers, and leading collaborators, we are developing a new wave of solutions that have the potential to transform how we heal injury and disease.”

According to Jordan Jacobs, managing partner, Radical Ventures, “We are very excited to partner with the excellent Aspect team to support the growth of their world-leading 3D bioprinting platform and the development of breakthrough technologies aimed at radically transforming human health.

 

Aspect Biosystems raises $20m in Series A funding

Aspect Biosystems

ASPECT BIOSYSTEMS ANNOUNCES US $20 MILLION SERIES A FINANCING TO ADVANCE ITS LEADING PLATFORM FOR 3D BIOPRINTING OF HUMAN TISSUE